UNDERSTANDING THE MECHANISM OF DRUG-RESISTANT AND TUMOR RECURRENCE IN LIVER CANCER
Abstract
Chemo-resistant and tumor recurrence are the major hurdle to overcome the cancer patients. Especially in hepatocellular carcinoma (HCC) is notoriously refractory to chemotherapy because of its tendency to develop multi-drug resistance (MDR), through various mechanisms. Aim: The current research is focussed on understanding the mechanism involved in chemo-resistant and tumor recurrence in liver cancer. Methods: Human hepatocellular carcinoma cell line (Huh7) was used entire study. Huh7 cells were cultured with known chemotherapeutic drugs such as 5-FU, Paclitaxel and Cisplatin-based on their Cmax concentration, and then these drug-treated cells were examined for chemoresistant and tumor recurrence properties through flow cytometry analysis, spheroid formation assay, and morphological analysis. Results: In morphological analysis confirm these all the chemo drugs were shown more cytotoxic effete than control, even though there were few viable cells noticed in cisplatin treatment. In flow cytometry analysis cisplatin pre-treated cells were well expressed LCSC marker such as CD133 and stem cell transduction factors like Oct-4 & Nanog than control. In addition to this, all the CD133 expressed cells also expressed to EpCAM. In spheroid formation assay, cisplatin pre-treated cells shown well-defined spheroid than control. Conclusion: LCSC plays a major role in chemoresistant and tumor recurrence through PI3K/Akt/mTOR, wnt-β catenin signaling, NF-kB signaling. So, targeting LCSC through EpCAM targeted therapy along with chemotherapy might be the better option for enhanced prognosis.
Keywords: LCSC, Chemoresistant, Tumor recurrence, Hepatocellular carcinoma.
Keywords:
Tumor recurrence, Hepatocellular carcinoma, ChemoresistantDOI
https://doi.org/10.22270/jddt.v8i5.1863References
Kimura Osamu, Kondo Yasuteru, Kogure Takayuki, et al. Expression of EpCAM increases in the hepatitis B related and the treatment-resistant hepatocellular carcinoma. BioMed Res Int Volume, 2014.
Kane Robert C, Farrell Ann T, Madabushi Rajanikanth, et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma, Onco, 2009, (14), 95 - 100.
Lee TK, Castilho A, Ma S, Ng IO. Liver cancer stem cells: implications for a new therapeutic target, Liver Int, 2009, (29) 955 - 965.
Gottesman, M. M. & Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem, 1993, (62), 385–427.
Park, J. G. et al. MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines, J Natl Cancer Inst, 1994, (86), 700–705.
Venkatesh, V. A. et al. Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition, Neoplasia, 2012, (14), 519–525.
Wang, L., Mosel, A. J., Oakley, G. G. & Peng, A, Deficient DNA damage signaling leads to chemoresistance to cisplatin in oral cancer, Mol Cancer Ther, 2012, (11), 2401–2409.
Comerford, K. M. et al, Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene, 2002, Cancer Res, (62), 3387–3394.
Li, Q. Q. et al, Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells, Clin Cancer Res, 2009, (15), 2657–2665.
Van Zijl, F. et al, A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression, Mol Cancer Ther, 2011, (10), 850–860.
Liang Wen1,* Chao Liang2,* Enjiang Chen1, Wei Chen1, et al, Regulation of Multi-drug Resistance in hepatocellular carcinoma cells is TRPC6/Calcium Dependent, Scientific Reports, 2016, (6), 23269.
Yang, Z. J., Chee, C. E., Huang, S. & Sinicrope, F. A. The role of autophagy in cancer: therapeutic implications, Mol Cancer Ther, 2011, (10), 1533–1541.
Martin, V. et al, Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumor stem cells, Br J Cancer, 2013, 108.
Baguley, B. C. Tumor stem cell niches: a new functional framework for the action of anticancer drugs, Recent Pat Anticancer Drug Discov, 2006, (1), 121–127.
Wu, Q., Yang, Z., Nie, Y., Shi, Y. & Fan, D. Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches, Cancer Lett, 2014, (347), 159–166.
Teicher, B. A. Acute and chronic in vivo therapeutic resistance, Biochem Pharmacol, 2009, (77), 1665–1673.
Esmatabadi MJ1, Bakhshinejad B, Motlagh FM, Babashah S, Sadeghizadeh M, Therapeutic resistance and cancer recurrence mechanisms: Unfolding the story of a tumor coming back, J Biosci, 2016, 41(3):497-506.
Is tumor growth sustained by rare cancer stem cells or dominant clones, Cancer Res, 2008, (68), 4018–402.
Dick JE, Looking ahead in cancer stem cell research, Nat Biotechnology, 2009, 27(1):44–46.
Gedaly R, Galuppo R, Daily MF, Shah M, Maynard E, et al, Targeting the Wnt/b-Catenin Signaling Pathway in Liver Cancer Stem Cells and Hepatocellular Carcinoma Cell Lines with FH535, PLoS ONE, 2014, 9(6), e99272.
Yi Chen, Dongke Yu, Hao Zhang, Hongwei He et al, CD133+EpCAM+ Phenotype Possesses More Characteristics of Tumor-Initiating Cells in Hepatocellular Carcinoma Huh7 Cells, Int. J. Biol. Sci, 2012, 8(7), 992-1004.
Taro Yamashita1, Junfang Ji1, Anuradha Budhu1 Marshonna Forgues1 et al, EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features, Gastroenterology, 2009, 136(3), 1012–1024.
Published
Abstract Display: 514 
PDF Downloads: 711 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.